Search
Showing search results for
Privo announces $2M FDA award for oral cancer product clinical study
Boston — The US Food and Drug Administration (FDA) had previously granted Privo Technologies’ (Privo) an IND to study PRV111, its nano-engineered chemotherapy and immunomodulatory product, in patients with oral cancer (NCT03502148). Today, Privo is excited to announce that it has been awarded ~ $2 million in funding from the FDA through its Office of Orphan Product Development […]